Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor

• Published in: Alzheimer's & dementia : translational research & clinical interventions Vol. 2; no. 3; pp. 202 - 212
• Main Authors: Timmers, Maarten, Van Broeck, Bianca, Ramael, Steven, Slemmon, John, De Waepenaert, Katja, Russu, Alberto, Bogert, Jennifer, Stieltjes, Hans, Shaw, Leslie M, Engelborghs, Sebastiaan, Moechars, Dieder, Mercken, Marc, Liu, Enchi, Sinha, Vikash, Kemp, John, Van Nueten, Luc, Tritsmans, Luc, Streffer, Johannes Rolf
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2016; Elsevier
• Subjects: Alzheimer's disease; Amyloid β; BACE inhibitors; BACE1; JNJ-54861911; Neurology; Other; β-secretase enzyme; JNJ-54861911; BACE1; BACE inhibitors; Alzheimer's disease; Amyloid β; β-secretase enzyme

Abstract Objectives Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, JNJ-54861911, were assessed after single and multiple dosing in healthy participants. Methods Two randomized, placebo-controlled, double-b...